Endometrial Cancer

Letrozole, Abemaciclib, and Metformin Triplet Therapy Shows Robust Activity in ER-Positive Endometrioid Endometrial Cancer

By MedXY 02/23/2026

A phase 2 trial demonstrates that combining letrozole, abemaciclib, and metformin achieves a 32% response rate and 60% clinical benefit rate in ER+ endometrioid endometrial cancer, with notable efficacy in CTNNB1-mutated tumors and an interesting pharmacokinetic interaction increasing metformin exposure.

news Oncology

Beyond Breast Cancer: ESR1 Mutations Identified as Prevalent Primary Drivers in NSMP Low-Grade Endometrial Cancer

By MedXY 01/13/2026

Results from the UTOLA trial reveal that ESR1 mutations, a hallmark of AI resistance in breast cancer, are present in 22% of metastatic NSMP low-grade endometrial cancer patients before endocrine therapy, suggesting a need for molecular stratification in clinical practice.

news Oncology

Molecular-Based Adjuvant Therapy Proves Safe and Effective in High-Intermediate Risk Endometrial Cancer: Results from the PORTEC-4a Trial

By MedXY 01/06/2026

The PORTEC-4a trial confirms that molecular profiling safely guides adjuvant treatment in high-intermediate risk endometrial cancer, reducing overtreatment by 46% while maintaining non-inferiority in locoregional control compared to standard brachytherapy.

news OB/GYN & Women's Health Oncology

Cervical Stromal Invasion Does Not Independently Predict Survival in Early-Stage Endometrial Cancer: A Multicenter Analysis

By MedXY 12/25/2025

A large-scale multicenter study indicates that cervical stromal invasion is not an independent prognostic factor for survival in early-stage endometrial cancer, challenging traditional staging assumptions when other high-risk features are controlled.

Clinical Updates news OB/GYN & Women's Health Oncology

Chemoradiotherapy Enhances Long-Term Survival in High-Risk Endometrial Cancer

By MedXY 09/25/2025

The PORTEC-3 trial demonstrates that adding platinum-based chemotherapy to pelvic radiotherapy significantly improves 10-year overall and recurrence-free survival in high-risk endometrial cancer, especially in patients with p53 abnormal tumors, emphasizing the importance of molecular profiling.

Clinical Updates OB/GYN & Women's Health Oncology Specialties

Innovative Combination Therapy in Recurrent Advanced Endometrial Cancer: Insights from the ENDOLA Phase I/II Trial

By MedXY 09/16/2025

The ENDOLA trial explored olaparib with metronomic cyclophosphamide and metformin, demonstrating a favorable safety profile and promising efficacy in heavily pretreated recurrent endometrial cancer patients, highlighting molecular subtype-dependent responses.

Clinical Updates OB/GYN & Women's Health Oncology Specialties

Metformin in Gynecologic Cancers: A Comprehensive Review of Evidence in Cervical, Ovarian, and Endometrial Cancer

By MedXY 09/16/2025

This review synthesizes recent evidence on metformin's therapeutic and prognostic roles in cervical, ovarian, and endometrial cancers, highlighting randomized trials, meta-analyses, and clinical outcomes with a focus on progression-free and overall survival.

OB/GYN & Women's Health Oncology Specialties

Evaluating Metformin Addition to Paclitaxel/Carboplatin in Advanced and Recurrent Endometrial Cancer: Insights from an NRG Oncology/GOG Phase II/III Trial

By MedXY 09/16/2025

This phase II/III study assessed whether adding metformin to standard paclitaxel and carboplatin improved outcomes in advanced and recurrent endometrial cancer. The trial was stopped early due to lack of survival benefit and potential harm, highlighting the need for alternative therapeutic strategies.

news OB/GYN & Women's Health Oncology Specialties

Age-Dependent Survival Outcomes in Early-Stage Endometrial Cancer: Fertility-Preserving Hormonal Therapy Versus Hysterectomy

By MedXY 08/31/2025

Fertility-preserving hormonal therapy for early-stage endometrial cancer shows comparable 5-year survival to hysterectomy in women under 40, but a significantly higher mortality risk in those aged 40-49 years, highlighting age as a critical factor in treatment decisions.

news OB/GYN & Women's Health Oncology Specialties

Fertility-Preserving Hormonal Therapy vs Hysterectomy in Early-Stage Endometrial Cancer: Survival Outcomes and Clinical Implications

By MedXY 08/31/2025

This analysis compares survival in young women with early-stage endometrial cancer treated with fertility-preserving hormonal therapy versus hysterectomy, highlighting survival equivalence in women under 40 years and increased mortality risk in older patients undergoing hormonal therapy.

OB/GYN & Women's Health Oncology Specialties

ChatGPT-4o versus Gynecologic Oncologists in Endometrial Cancer Patient Communication: A Prospective Comparative Study

By MedXY 08/27/2025

This study compares ChatGPT-4o and gynecologic oncologists in addressing endometrial cancer patient questions, showing superior AI accuracy, empathy, and completeness, though lengthy responses may challenge patient comprehension.